Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115817) titled 'A Clinical Study of Biejia-Ruangan compound Tablets for Preventing Recurrence and Metastasis in Patients with Primary Hepatocellular Carcinoma After Radical Treatment' on Dec. 31, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Beijing Ditan Hospital, Capital Medical University
Condition:
Primary Hepatocellular Carcinoma
Intervention:
Experimental Group:Biejia Ruangan compound+Routine Treatment
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-31
Target Sample Size: Experimental Group:469;Control Group:235;
Countries of Recruitment:
Chin...